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Abstract 
Background:  Diet has been proposed to modulate the risk of asthma in children and adults. An increasing body of 
epidemiological studies have been published in the last year investigating the association between dietary intake and 
asthma. As part of the Evidence‑Based Clinical Practice Guideline Task Force on ‘Lifestyle Interventions in Allergy and 
Asthma’ funded by the European Academy of Allergy and Clinical Immunology, we will use a systematic approach to 
review the evidence from published scientific literature on dietary intake and asthma in children and adults.
Methods:  This systematic review will be carried out following the PRISMA guidelines. The protocol has been pub‑
lished in PROSPERO (CRD42016036078). We will review the evidence from epidemiological studies in children (from 
the age of 2 years) and adults and dietary intake of foods and nutrients.
Discussion: The findings from this review will be used as a reference to inform guideline recommendations.
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Background
Since the late 60  s, a sharp increase in the incidence of 
asthma was observed, which seems to have reached a 
plateau in the last 10 years in some countries [1], but it 
continues to rise in others [2]. Asthma prevalence and 
poor asthma control [3] represent a major problem of 
public health and a socio-economic burden, particularly 
in developed countries as well as in nations with fast 
growing economies where the highest rates of disease 
have been reported [3]. This trend has been accompa-
nied by noticeable changes in lifestyle. Improved access 
to technology and development have led to a more sed-
entary life. Easier access to food and a shift in the eating 
patterns from naturally sourced to processed food have 
been accompanied by a reduced intake of fresh fruits and 
vegetables, less fibre, and an increased intake foods rich 
in refined sugar.
It is known that oxidative stress and airway inflamma-
tion are central features in the manifestation of asthma 
[4], which might be exacerbated by the poorer quality of 
the diet [5]. The possible effect of diet on asthma, par-
ticularly in relation to the role of dietary antioxidants 
and polyunsaturated fatty acids has been investigated in 
numerous observational studies [6]. Current evidence 
suggests that antioxidant vitamins C and E and a higher 
intake of fresh vegetables and fruits might have a pro-
tective effect on asthma, but most of the findings are 
still considered weak due to the cross-sectional design 
of the studies and the heterogeneity in diet assessment 
between them [7]. Intervention trials have added little so 
far to understand the role of nutrients on asthma, which 
opens the question of whether the sources of nutrients 
matter (e.g. diet vs supplements). We recently completed 
an overview of high quality systematic reviews on diet 
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intake of fruits and vegetables as well as adherence to a 
Mediterranean diet during childhood might reduce the 
risk of asthma in children. The evidence from studies in 
adults was less clear.
In this systematic review we aim to comprehensively 
assess the existing scientific literature on the relation-
ship between to dietary intake and the risk of asthma in 
children and adults, published in the last 5 years. There 
have been few high quality systematic reviews (AMSTAR 
score  ≥  32) published since 2011 and none included 
both children and adults as target populations. We will 
not include maternal or infant dietary intake (solids or 
breastfeeding) as three large systematic reviews have 
just been completed covering these age groups (Inter-
national Prospective Register of Systematic Reviews 
[PROSPERO http://www.crd.york.ac.uk/PROSPERO/
search.asp] references CRD42013003802—REVIEW A; 
CRD42013004239—REVIEW B; CRD42013004252—
REVIEW C).
The scope of our Task Force is to provide evidence on 
dietary intake and dietary habits in relation to risk of 
asthma, wheeze (recurrent or persistent), and bronchial 
hyper-responsiveness (BHR). Our findings will serve as a 
reference to inform guidelines on dietary habits in sus-
ceptible and general population to reduce the risk and/
or severity of asthma in children and adults. This system-
atic review protocol has been prepared following the new 
PRISMA-P guidelines [9].
Objectives
The aim of this systematic review is to evaluate the asso-
ciation between dietary intake and risk of asthma in chil-
dren and adults. To this end, we will seek to answer the 
following questions:
1. Does exposure to diet (as a whole, as grouped or 
individual foods) during childhood influence the risk 
of asthma ?
2. Does exposure to diet (as a whole, as grouped or indi-
vidual foods) in adults influence their risk of asthma ?
Methods
Eligibility criteria
Studies will be selected according to the criteria outlined 
below.
Study designs
We will include randomised controlled trials (RCT), 
quasi RCT, as well as cohort (prospective or retro-
spective) studies, nested case–control studies, other 
case–control studies and cross-sectional studies (includ-
ing those with retrospective data).
Participants
We will investigate the role of diet on asthma in children 
from the age of 2 years old to adulthood. Participants of 
any age group within this range, unrestricted by disease 
severity, previous or current treatment, will be included.
Interventions
The objective of this systematic review is to collate the evi-
dence on intake of foods and nutrients on asthma as a base-
line for guidelines, a decision was made a priori to examine 
the evidence from studies that included actual food or 
nutrients (i.e. not supplements). Observational studies that 
used a dietary questionnaire to capture dietary intake will 
be included. Intervention studies with actual food rather 
than supplementation will also be included. Foods and 
nutrients will be classified, whenever possible, according to 
their nutritional properties and/or similarities.
Comparator(s)/control
All comparators will be included in the description of 
eligible studies. We will include report of different doses 
of forms of an exposure (e.g. frequency/total daily grams 
intake). For the studies that only report frequency of 
intake of foods we will report differences as binary com-
parisons e.g. weekly versus never, daily versus never.
Outcomes
The primary outcomes are asthma or wheeze. Accept-
able definitions of asthma will include ‘doctor diagnosed 
asthma’, ‘self-reported asthma’, ‘ever had asthma’, ‘persis-
tent asthma’, ‘allergic asthma’, ‘atopic asthma’, ‘wheeze in 
the last 12 months’, ‘current wheeze’, ‘recurrent wheeze’ or 
any other definition of asthma clearly documented in the 
selected study. Outcomes will be collected as reported. Due 
to possible variations in disease definitions, we will extract 
definitions of outcomes as reported in individual studies. 
We will extract outcomes in all data forms (e.g. dichoto-
mous, continuous,) as reported in the included studies.
Timing
Eligible studies will be selected for inclusion regardless 
of the time length between exposure and outcome. Pro-
spective and retrospective exposure will be considered, 
as well as cross-sectional.
Setting
There will be no restrictions by type of setting.
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Language
We will include articles reported in the English language.
Exclusion criteria
This systematic review is centred on the role that diet 
might have on asthma outcomes, therefore the exclusion 
criteria applies to those factors listed below:
 1. Non-comparative studies
 2. Reviews
 3. Non-human study
 4. In vitro/In vivo studies
 5. Chronic obstructive pulmonary disease (COPD)
 6. Chronic bronchitis
 7. Allergy/Food allergy
 8. Eczema/atopic dermatitis
 9. Atopy
 10. Exposure in pregnancy (in utero)
 11. Breastfeeding
 12. Use of nutritional supplements not naturally 
extracted from the diet (e.g. capsules of vitamin a, 
C, E, fish oils, fish capsules, mineral, pro- and pre-
biotic, or herbal supplementation)
 13. Food challenge (e.g. white or red wine given as a 
food challenge rather than studied as usual intake)
 14. Food avoidance for allergy prevention (i.e. antigen 
protein cow milk)
 15. Nutrients measured in blood (serum or plasma)
 16. Work related exposure to foods (e.g. bakery, bakers)
 17. Occupational asthma
 18. Obesity/weight loss [low calorie diets]/exercise
 19. Indoor pollution (e.g. cooking gas)
 20. Medication alone as treatment for asthma (e.g. cor-
ticosteroids, montelukast, etc.) but medication com-
bined or in parallel to food intake will be accepted
 21. Asthma grouped with other diseases such as COPD 
or bronchitis
 22. Sodium chloride/sodium 0.9 % (as saline solution e.g. 
intravenous) but dietary or supplemented sodium 
will be included
 23. Ethanol as intravenous or oral supplementation—
consumption of alcohol will be accepted
 24. Exposure to rural-related environmental risk factors 
that do not include any specific dietary exposures
 25. Inhalation of milk proteins or aerosol-related food 
particles in the air
 26. Studies in which participants where defined by a dis-
ease state (other than the relevant outcomes studied 
here) e.g. children or adults with specific nutritional 
deficiencies.
Information sources
Literature search strategies have been developed using 
medical subject headings (MeSH) and text words related 
to asthma or wheeze. We will search MEDLINE (OVID 
interface), EMBASE (OVID interface), Web of Science, 
and the Cochrane Central Register of Controlled Trials 
(CENTRAL; Wiley interface). The electronic database 
search will be supplemented by searching for trial proto-
cols of food intervention by searching through metaReg-
ister (http://www.controlled-trials.com/mrct/).
Search strategies
We will search for eligible studies published in the last 
5 years (1st January 2011–2nd March 2016). The specific 
search strategies have been designed by VGL in collabo-
ration with a Librarian at Imperial College with expertise 
in systematic review searching. The strategies were devel-
oped with input from the co-authors to ensure that rel-
evant outcomes and exposure terms were included. The 
search strategies were also reviewed by a second Librarian, 
not involved in the project. The search strategies for MED-
LINE, Web of Science and Cochrane Library are included 
in Additional file 1: Appendix. Per reviewed abstracts pre-
sented in scientific conferences will also be screened. We 
will check if these were followed by the corresponding 
peer reviewed publication. The International Clinical Tri-
als Registry Platform Search Portal and ClinicalTrials.gov 
will be searched for ongoing or recently completed trials. 
We will also search for studies in progress or completed 
but unpublished using http://apps.who.int/trialsearch/. 
The bibliography of all selected eligible papers will be 
examined for potential relevant additional publications.
We will also separately search for existing systematic 
reviews published in the same period as in our review 
(2011–2016) which cover relevant exposures and out-
comes. These findings will be used in the Discussion sec-
tion as part of the interpretation of our findings.
Data management
Relevant study characteristics and results will be 
recorded in a spreadsheet file (Excel). We will pilot the 
file to ensure that the descriptors are clear. A template 
has been prepared by the research team and a calibration 
exercise will be undertaken to pilot and refine the screen-
ing questions.
Selection process
Two members of the research team (VGL and SDG) will 
independently review titles and abstracts of all identi-
fied studies. The search strategies will be piloted and 
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checked for completeness to ensure that as far as pos-
sible, all potentially eligible titles are captured. The full 
text of the paper will also be independently assessed by 
VGL and SDG, and will be assessed for eligibility against 
the inclusion and exclusion criteria. Any discrepancies 
will be resolved through discussions with the research 
team. Electronic records will be kept regarding included 
and excluded studies for audit purposes, specifying rea-
sons for any exclusion. Full text articles will be reviewed 
in duplicate (by two research team members—VGL and 
SDG), and studies for inclusion will be selected—any 
discrepancies will be resolved through discussions with 
the research team. The reasons for the exclusion of any 
relevant studies will be recorded. Neither of the review 
authors will be blind to the journal titles or to the study 
authors or institutions.
Data collection process
A pilot of the data extraction form will be undertaken 
using a minimum of 5 papers, after which the extrac-
tion form will be amended/updated as necessary. The 
data extraction form will be used to extract the relevant 
data fields from each included study independently (by 
two research team members—VGL and SDG). Data 
abstracted will include demographic information, meth-
odology, intervention details, and all reported relevant 
outcomes. Reviewers will resolve disagreements by dis-
cussion, and one of two arbitrators (AM or LD) will adju-
dicate unresolved disagreements. We will contact study 
authors to resolve any uncertainties. Where appropriate 
data will be entered into STATA statistical software for 
meta-analysis.
Data on exposures
We will extract all effect estimates available for any die-
tary exposure studied, as well as all the relevant study 
characteristics. If effect sizes cannot be calculated, we 
will report the results as a narrative. We anticipate to 
find wide variations in the way dietary data is recorded, 
both with regards to frequency of consumption and to 
levels of intake compared. Once the data is entered, 
we will group exposures according to similarities in 
time and comparison levels (e.g. weekly vs never; high-
est quintile of intake vs lowest). Data will be extracted 
either using raw values, crude estimates of effect (includ-
ing odds ratios, risk ratios, incidence rate ratios, haz-
ard ratios, mean differences) or as adjusted estimates of 
effect. Adjusted estimates of effect will be used in prefer-
ence, where available.
Outcomes and prioritisation
The primary outcome will be asthma or wheeze. In the 
case of pre-school children ‘wheezing illness’ will also be 
accepted as proxy definition for asthma. As a secondary 
outcome, we will include bronchial hyper-responsiveness 
(BHR). Lung function measurements will be included as 
outcomes only if used as a direct measure of asthma sta-
tus, asthma control, or severity in patients with asthma. 
In children and adults, any established definition of 
asthma or wheeze will be accepted.
Risk of bias (quality) assessment
Study level bias
We will only include RCTs if these are food interven-
tions (e.g. Mediterranean diet, high fruit intake inter-
vention). If we identify any such trials, the risk of bias 
will be assessed using the Cochrane Collaboration risk 
of bias tool, which includes sequence generation, alloca-
tion concealment, blinding, incomplete outcome data, 
and selective outcome reporting, and other bias [10]. 
RCTs will be considered at low risk of bias where the 
risk of bias is judged to be low for all key domains of the 
Cochrane Handbook for Systematic Reviews of Inter-
ventions [11].
The risk of bias in observational studies will be 
assessed using the National Institute for Clinical Excel-
lence Methodological Checklist for cohort, and case–
control and cross-sectional studies, which includes 
considerations of subject selection, assessment of expo-
sure and outcome, and measures to assess confounding 
[12]. Studies will be considered at low risk of bias where 
most of the criteria in the checklist are addressed, and 
those that are not addressed or not reported are judged 
unlikely to change the study findings. For both RCTs 
and cohort studies, a level of <20 % loss to follow up will 
generally be accepted as representing low risk of bias 
from incomplete outcome data, if there are no other fea-
tures to suggest increased risk of bias. For all studies, a 
summary Table of Study Characteristics according to 
the PICO guidelines from NICE [13] will be presented, 
which will include the population characteristics, 
methods used for assessing exposure and for outcome 
assessment.
Strategy for data synthesis
Separate analyses will be undertaken for each group 
of similar outcome assessment methods and for each 
intervention/exposure. Results for randomised or quasi-
randomised controlled trials, prospective cohort or lon-
gitudinal studies, or where appropriate retrospective 
cohort studies, nested case–control studies, case–con-
trol and cross-sectional studies will be reported sepa-
rately for each comparison. If the studies are sufficiently 
homogeneous in terms of design and comparator, we 
will conduct meta-analyses using a random-effects 
model.
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Measures of treatment/exposure effect
Data from individual studies will be pooled using the 
generic inverse variance method. Pooled results for 
binary outcomes will be presented as relative risks s 
with 95 % confidence intervals and 2-sided p values, and 
also expressed as risk differences where possible. Rel-
evant results will be presented in Summary of Findings 
tables. For dichotomous outcomes, we will use odds 
ratio (OR) with 95 % confidence interval (CI). Continu-
ous outcomes (e.g. BHR slope) will be analysed using 
weighted mean differences (with 95 % CI) or standard-
ised mean differences (95  % CI) if different measure-
ment scales are used. All analyses will be performed 
using STATA. Non-quantitative data will be presented 
descriptively.
Assessment of heterogeneity
We will examine the heterogeneity between studies by 
considering variability in participant factors (e.g. age, 
setting, type of diet or dietary exposure studied). Statis-
tical heterogeneity will be quantified using I-squared (I2; 
0–40 % might not be important; 30–60 % may represent 
heterogeneity; >60 % may represent moderate heteroge-
neity; >75 % considerable heterogeneity).
Analysis of subgroups or subsets
Increased disease risk—studies of populations at 
increased risk for asthma will be separately analysed—for 
example children with a family history of atopic disease.
Narrative synthesis
A systematic narrative synthesis will be provided with 
information presented in the text and tables to summa-
rise and explain the characteristics and findings of the 
included studies. The narrative synthesis will explore the 
relationship and findings both within and between the 
included studies.
Meta‑bias assessment
Publication bias will be assessed using funnel plots and 
Egger’s test. Where asymmetry is evident on the funnel 
plot, a trim and fill analysis will be used. Possible causes 
for asymmetry other than publication bias (e.g. between 
study heterogeneity) will also be considered.
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